IRCT20130811014330N4 IRCT 2018-10-30 Mashhad University of Medical Sciences,vice chancellor for research The effect of Curcumin on LP(a) and hs-CRP in diabetes patients and concurrent coronary artery diseases( coronary artery disease less than 50% obstruction) The effects of Curcumin on serum level changes of lipoprotein (a) and hs-CRP as novel biomarkers in type 2 diabetic patients with coronary artery disease of less than 50% obstruction: A double-blind clinical trial study 2017-08-01 anticipated 64 Complete https://irct.ir/trial/13933 interventional Randomization: Randomized, Blinding: Double blinded, Placebo: Used, Assignment: Parallel, Purpose: Treatment, Randomization description: simple randomization through random number table: included patients were randomized to receive curcmin or matched-placebo for a period of 3 months. The groups were also matched regarding age. , individual, computer soft-wares, Blinding description: participants, principle investigator particularly, healthcare providers (Physicians, nurses, physiotherapists, etc.) . who care for participants during the trial, data collectors, outcome assessors. For the control group, placebo was prescribed in the shape and color and size of the drug. 3 CAD. Intervention 1: The intervention group received routine treatment of heart disease and DMII in accordance with, the administration of curcumin. 1 Soft gel ((SinaCurcumin® (as nano-micelle 80 mg per day)) will be gave to patients for three months. Also, people underwent routine treatments of B-blockers, Aspirins, diuretic drugs, Athro-statins, vasodilators such as NO for heart diseases and metformin and glibangelamide for diabetes. Intervention 2: Control group: In this group, the placebo contains inert oil, with the same color as the drug that the drug manufacturer has produced, was given to patients with heart disease and diabetes for a period of three months, in terms of shape and size, similar to the medicine. Undecided - It is not yet known if there will be a plan to make this available Justification or reason for indecision in sharing IPD is "There is no further information"